{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?legislature.prefLabel=House+of+Commons&tablingMemberConstituency=Lichfield&hansardHeading=Coronavirus%3A+Vaccination", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?legislature.prefLabel=House+of+Commons&tablingMemberConstituency=Lichfield&hansardHeading=Coronavirus%3A+Vaccination", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?legislature.prefLabel=House+of+Commons&tablingMemberConstituency=Lichfield&_metadata=all&hansardHeading=Coronavirus%3A+Vaccination", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&legislature.prefLabel=House+of+Commons&tablingMemberConstituency=Lichfield&hansardHeading=Coronavirus%3A+Vaccination", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?legislature.prefLabel=House+of+Commons&tablingMemberConstituency=Lichfield&hansardHeading=Coronavirus%3A+Vaccination", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?legislature.prefLabel=House+of+Commons&tablingMemberConstituency=Lichfield&hansardHeading=Coronavirus%3A+Vaccination", "items" : [{"_about" : "http://data.parliament.uk/resources/1400704", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1400704/answer", "answerText" : {"_value" : "<p>The criteria for adding new vaccination centres or sites to the National Booking System (NBS) is dependent upon the delivery model. All community pharmacy vaccination sites and mass vaccination centres are automatically added to the NBS regardless of their capacity. Regional systems prioritise the addition of sites to the NBS according to local need and may also include smaller sites such as \u2018pop-ups\u2019 to meet local care needs.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4447", "label" : {"_value" : "Biography information for Maggie Throup"}
        }
        , "answeringMemberConstituency" : {"_value" : "Erewash"}
        , "answeringMemberPrinted" : {"_value" : "Maggie Throup"}
        , "dateOfAnswer" : {"_value" : "2022-03-02", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-03-02T10:04:35.157Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-01-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will add to the National Booking System covid-19 vaccination centres which have the capacity of 500 vaccinations a week but which are below the current 1,000 vaccinations per week threshold.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/280", "label" : {"_value" : "Biography information for Michael Fabricant"}
      }
      , "tablingMemberConstituency" : {"_value" : "Lichfield"}
      , "tablingMemberPrinted" : [{"_value" : "Michael Fabricant"}
      ], "uin" : "99302"}
    , {"_about" : "http://data.parliament.uk/resources/1399371", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1399371/answer", "answerText" : {"_value" : "<p>We have no current plans for a fourth mass COVID-19 vaccination programme.<\/p><p>The Joint Committee on Vaccination and Immunisation (JCVI) has stated that it is not known whether recurrent boosters will be required in the long term. The current advice on booster vaccinations applies to this highly active phase of the pandemic. We will continue to be informed by the latest scientific advice from the JCVI on whether further action is required.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4447", "label" : {"_value" : "Biography information for Maggie Throup"}
        }
        , "answeringMemberConstituency" : {"_value" : "Erewash"}
        , "answeringMemberPrinted" : {"_value" : "Maggie Throup"}
        , "dateOfAnswer" : {"_value" : "2022-01-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-01-10T17:55:09.213Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-01-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans he has to initiate a fourth mass covid-19 vaccination programme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/280", "label" : {"_value" : "Biography information for Michael Fabricant"}
      }
      , "tablingMemberConstituency" : {"_value" : "Lichfield"}
      , "tablingMemberPrinted" : [{"_value" : "Michael Fabricant"}
      ], "uin" : "96759"}
    , {"_about" : "http://data.parliament.uk/resources/1399372", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1399372/answer", "answerText" : {"_value" : "<p>Recent analysis supports our understanding that the Pfizer/BioNTech and Moderna vaccines, which are currently being deployed in the UK, appear to work well against the current dominant variants of COVID-19 after a booster-dose. Continuing to administer these vaccines at scale remains essential in our path out of the pandemic.<\/p><p> <\/p><p>The Government continues to assess our existing vaccine portfolio against current variants, working closely with vaccine manufacturers and the UK Health Security Agency to understand the efficacy of our current vaccine portfolio against new variants.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2022-01-12", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-01-12T09:49:01.64Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2022-01-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what plans there are to manipulate the covid-19 vaccine to sensitise it to the omicron and other variants; and when he estimates such vaccines might become available.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/280", "label" : {"_value" : "Biography information for Michael Fabricant"}
      }
      , "tablingMemberConstituency" : {"_value" : "Lichfield"}
      , "tablingMemberPrinted" : [{"_value" : "Michael Fabricant"}
      ], "uin" : "96760"}
    , {"_about" : "http://data.parliament.uk/resources/1356481", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1356481/answer", "answerText" : {"_value" : "<p>We are planning for all scenarios in the fight against COVID-19 and the\u202fVaccine Taskforce is taking a number of steps to ensure the UK is prepared to respond to current and emerging COVID-19 variants as quickly as possible.<\/p><p> <\/p><p>However, current data suggests that all deployed COVID-19 vaccines in the UK - AstraZeneca, Pfizer and Moderna -\u202foffer protection against the prevalent virus variants currently\u202fcirculating in the UK, and recent data indicates that the Pfizer vaccine remains effective against Beta variant.<\/p><p> <\/p><p>We continue to assess the efficacy of the vaccines currently in our portfolio\u202fagainst\u202fnew and future variants of the virus and continue to work closely with vaccine manufacturers to ensure that vaccines\u202fthat\u202fhave already received UK regulatory approval could be suitably updated, where possible and where needed, to remain effective against emerging variants of SARS-CoV-2.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2021-09-23", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-09-23T16:43:51.443Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-09-17", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what plans his Department has to acquire vaccines to provide protection from the most recent variants of covid-19; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/280", "label" : {"_value" : "Biography information for Michael Fabricant"}
      }
      , "tablingMemberConstituency" : {"_value" : "Lichfield"}
      , "tablingMemberPrinted" : [{"_value" : "Michael Fabricant"}
      ], "uin" : "50943"}
    , {"_about" : "http://data.parliament.uk/resources/1348830", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1348830/answer", "answerText" : {"_value" : "<p>The Joint Committee on Vaccination and Immunisation\u2019s (JCVI) interim advice on a potential COVID-19 booster vaccination programme states that vaccines designed specifically against variants of concern will not be available in time for booster revaccination this autumn. The use of variant vaccines will be considered by the JCVI in due course.<\/p><p>Final decisions on the timing, scope and cohort eligibility of any COVID-19 vaccine booster\u202fprogramme will be confirmed once the JCVI has provided their final advice. The JCVI\u2019s advice will take into account the latest epidemiological situation, additional scientific data from trials such as COV-Boost, surveillance of the effectiveness of the vaccines over time and emerging variants.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-09-06", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-09-06T11:33:35.787Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-07-20", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether the proposed autumn Covid-19 booster vaccination programme will include a modified vaccine with improved efficacy against the (a) delta and (b) other covid-19 variants.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/280", "label" : {"_value" : "Biography information for Michael Fabricant"}
      }
      , "tablingMemberConstituency" : {"_value" : "Lichfield"}
      , "tablingMemberPrinted" : [{"_value" : "Michael Fabricant"}
      ], "uin" : "36517"}
    , {"_about" : "http://data.parliament.uk/resources/1329404", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1329404/answer", "answerText" : {"_value" : "<p>The UK Government has secured early access to 397 million vaccines doses through supply agreements with six separate vaccine developers. This includes agreements with:<\/p><p> <\/p><ul><li>Pfizer/BioNTech for 100 million doses<\/li><li>University of Oxford/AstraZeneca for 100 million doses<\/li><li>Moderna for 17 million doses<\/li><li>Novavax for 60 million doses<\/li><li>Janssen for 20 million doses<\/li><li>Valneva for 100 million doses<\/li><\/ul><p> <\/p><p>In addition, the Government has a reservation agreement with GlaxoSmithKline/Sanofi Pasteur for 60 million doses and a non-binding agreement with CureVac for 50 million doses.<\/p><p> <\/p><p>The Government is working closely with vaccine manufacturers and Public Health England to understand the efficacy of our current vaccine portfolio against new variants and will continue to monitor the picture with variants as it develops. <br> <br> The Government announced on 3 June 2021 that it has started commercial negotiations with AstraZeneca for future supplies of the University of Oxford/AstraZeneca vaccine that have been adapted to tackle the Beta variant first identified in South Africa.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-06-14", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-06-14T15:23:17.377Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-06-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, whether advanced orders placed for new covid-19 vaccines such as the Janseen vaccine will be designed around the latest variants known to be in existence at the time of delivery.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/280", "label" : {"_value" : "Biography information for Michael Fabricant"}
      }
      , "tablingMemberConstituency" : {"_value" : "Lichfield"}
      , "tablingMemberPrinted" : [{"_value" : "Michael Fabricant"}
      ], "uin" : "10158"}
    , {"_about" : "http://data.parliament.uk/resources/1299369", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1299369/answer", "answerText" : {"_value" : "<p>The Department has not currently commissioned any research into COVID-19 vaccines which can be delivered through an adhesive patch but the National Institute for Health Research, as the biggest public funder of health research in the United Kingdom, continues to welcome funding applications for research into any aspect of human health, including on COVID-19 vaccine related research.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
        }
        , "answeringMemberConstituency" : {"_value" : "Charnwood"}
        , "answeringMemberPrinted" : {"_value" : "Edward Argar"}
        , "dateOfAnswer" : {"_value" : "2021-03-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-03-15T13:23:04.77Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-03-03", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, further to the Answer of 3 March to Question 154738, what support his Department is providing for (a) research on and (b) trials of vaccines offering immunity to covid-19 which can be delivered by gradual absorption through the skin using an adhesive patch.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/280", "label" : {"_value" : "Biography information for Michael Fabricant"}
      }
      , "tablingMemberConstituency" : {"_value" : "Lichfield"}
      , "tablingMemberPrinted" : [{"_value" : "Michael Fabricant"}
      ], "uin" : "162509"}
    , {"_about" : "http://data.parliament.uk/resources/1287103", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1287103/answer", "answerText" : {"_value" : "<p>Through a joint rolling research call for COVID-19 research between the National Institute for Health Research and UK Research and Innovation, funding of over £500,000 has been committed to a study looking at the safety and immunogenicity of two candidate COVID-19 vaccines administered to the respiratory tract in aerosol form, with an expected end date in August 2021.<\/p><p>In addition, Innovate UK, have been managing the delivery of £75 million of the £110 million Department-funded UK Vaccine Network programme. Nine Departmental projects within this portfolio were repurposed to identify other COVID-19 vaccines solutions. Also, two Innovate UK grants worth over £2.2 million in total, were awarded to Stabilitech, now known as IosBio, to assess its COVD-19 vaccine candidate that has an oral capsule delivery system in animal efficacy studies. This technology is now being tested in participants in clinical trials in South Africa and the United States.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
        }
        , "answeringMemberConstituency" : {"_value" : "Charnwood"}
        , "answeringMemberPrinted" : {"_value" : "Edward Argar"}
        , "dateOfAnswer" : {"_value" : "2021-03-03", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-03-03T16:21:42.95Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-02-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what support his Department is providing for (a) research on and (b) trials of oral vaccines offering immunity to covid-19.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/280", "label" : {"_value" : "Biography information for Michael Fabricant"}
      }
      , "tablingMemberConstituency" : {"_value" : "Lichfield"}
      , "tablingMemberPrinted" : [{"_value" : "Michael Fabricant"}
      ], "uin" : "154738"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 8, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}